4.49
0.11 (2.51%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | BioAge Labs, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.75 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 3.62% |
| % Held by Institutions | 67.48% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sands Capital Ventures, Llc | 31 Dec 2024 | 786,353 |
| Redpoint Management, Llc | 31 Dec 2024 | 383,255 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (Citigroup, 11.36%) | Hold |
| 5.00 (Morgan Stanley, 11.36%) | Sell | |
| Median | 5.00 (11.36%) | |
| Average | 5.00 (11.36%) | |
| Total | 1 Hold, 1 Sell | |
| Avg. Price @ Call | 4.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 24 Mar 2025 | 5.00 (11.36%) | Hold | 4.49 |
| Morgan Stanley | 07 Mar 2025 | 5.00 (11.36%) | Sell | 4.55 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Mar 2025 | Announcement | BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 |
| 17 Mar 2025 | Announcement | BioArctic receives Orphan Drug Designation for exidavnemab the US |
| 20 Feb 2025 | Announcement | BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference |
| 12 Feb 2025 | Announcement | BIOA ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against BioAge Labs, Inc. (BIOA) |
| 28 Jan 2025 | Announcement | BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |